Search results
Results from the WOW.Com Content Network
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Esketamine is the second drug to be approved for treatment-resistant depression by the FDA, following olanzapine/fluoxetine (Symbyax) in 2009. [ 25 ] [ 50 ] Other agents, like the atypical antipsychotics aripiprazole (Abilify) and quetiapine (Seroquel), have been approved for use in the adjunctive therapy of major depressive disorder in people ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment. Beth Greenfield. January 22, 2025 at 8:28 PM ... Spravato is made from esketamine, ...
However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine. This article examines Medicare coverage for ketamine infusion, coverage ...
The US Food and Drug Administration (FDA) first approved the use of intranasal esketamine —an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019, [11] leading to the creation and expansion of telemedicine-based companies that practice KAP, such as Mindbloom. [12]
XW10508 is an orally active prodrug of esketamine, an NMDA receptor antagonist, which is under development for the treatment of major depressive disorder and chronic pain. [1] [4] [2] [3] It is taken by mouth. [1] [2] [3] The drug is a novel esketamine analogue and conjugate that acts as a prodrug of esketamine. [3]
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]